Comparison Study of Operation and PEIT for Small, Solitary Hepatocellular Carcinoma (HCC)
This study has been completed.
Sponsor:
Seoul National University Hospital
Information provided by:
Seoul National University Hospital
ClinicalTrials.gov Identifier:
NCT00357422
First received: July 26, 2006
Last updated: April 18, 2013
Last verified: April 2013
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to choose the preferred treatment modality for solitary, small hepatocellular carcinoma.
| Condition | Intervention | Phase |
|---|---|---|
|
Hepatocellular Carcinoma |
Procedure: Operation Procedure: Percutaneous ethanol injection therapy |
Phase 3 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Crossover Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Prospective Randomized Trial of the Effective Therapy for Small, Solitary HCC Comparing Operation and Percutaneous Ethanol Injection Therapy |
Further study details as provided by Seoul National University Hospital:
Primary Outcome Measures:
- overall survival rate [ Time Frame: 5 year ] [ Designated as safety issue: Yes ]
Secondary Outcome Measures:
- disease free survival rate and recurrence rate [ Time Frame: 5 year ] [ Designated as safety issue: Yes ]
| Estimated Enrollment: | 206 |
| Study Start Date: | October 2005 |
| Study Completion Date: | April 2013 |
| Primary Completion Date: | April 2013 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Active Comparator: surgery |
Procedure: Operation
No drug needed
Other Name: surgery
|
| Active Comparator: local therapy |
Procedure: Percutaneous ethanol injection therapy
99% ethanol, 2-4cc per one session, two to three sessions per single procedure for one week
Other Name: PEIT
|
Detailed Description:
To compare the below things between operation group and percutaneous ethanol injection therapy (PEIT) group:
Survival
- 5 year overall survival rate
- Disease free survival rate
Recurrence
- Cumulative recurrence rate
Eligibility| Ages Eligible for Study: | 20 Years to 70 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- The evidences of hepatitis B virus (HBV)&/or hepatitis C virus (HCV) infection or liver cirrhosis
- Single tumor nodule with Child-Pugh classification A (serum albumin ≥ 3.2 g/dL)
- The maximal, longest diameter of tumor mass measured by CT finding should be less than 2 cm
- Only for the newly detected HCCs which were not treated before
- It should be compatible with the typical finding of hepatocellular carcinomas (HCCs) radiologically (MD CT or dynamic MRI)
- Without portal hypertension
Exclusion Criteria:
- In case of hepatic vein or portal vein invasion radiologically (CT or MRI)
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00357422
Locations
| Korea, Republic of | |
| Seoul NUH | |
| Seoul, Chongno-gu, Korea, Republic of, 110-744 | |
Sponsors and Collaborators
Seoul National University Hospital
Investigators
| Principal Investigator: | J H Yoon, Professor | Seoul National University Hospital |
More Information
No publications provided
| Responsible Party: | Jung Hwan Yoon/professor, Seoul National University Hospital |
| ClinicalTrials.gov Identifier: | NCT00357422 History of Changes |
| Other Study ID Numbers: | 07-2007-006 |
| Study First Received: | July 26, 2006 |
| Last Updated: | April 18, 2013 |
| Health Authority: | Korea: Food and Drug Administration |
Keywords provided by Seoul National University Hospital:
|
HCC, operation, percutaneous ethanol injection |
Additional relevant MeSH terms:
|
Carcinoma Carcinoma, Hepatocellular Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Neoplasms Adenocarcinoma Liver Neoplasms Digestive System Neoplasms Neoplasms by Site Digestive System Diseases |
Liver Diseases Ethanol Anti-Infective Agents, Local Anti-Infective Agents Therapeutic Uses Pharmacologic Actions Central Nervous System Depressants Physiological Effects of Drugs Central Nervous System Agents |
ClinicalTrials.gov processed this record on May 16, 2013